The federal government has cracked open a door it kept sealed for decades - and the cannabis industry isn't sure whether to walk through it. On April 29, the Drug Enforcement Administration's Diversion Control Division launched an application portal allowing state-licensed medical cannabis dispensaries to seek expedited Schedule III registration, following a sweeping order signed by Acting Attorney General Todd Blanche that moved FDA-approved cannabis products and state-licensed medical cannabis from Schedule I to Schedule III under the Controlled Substances Act. The 60-day window to apply for expedited review closes June 26.
What Rescheduling Actually Means - and What It Doesn't
For context: Schedule I under the CSA designates a substance as having no accepted medical use and a high potential for abuse. Schedule III, by contrast, acknowledges accepted medical utility and carries significantly lighter regulatory burdens. The practical difference is enormous. It's what allows pharmaceutical manufacturers to operate in the open, access conventional banking, and deduct ordinary business expenses from federal taxes - the last of which is particularly consequential for cannabis operators long trapped by Section 280E, the tax code provision that barred them from those deductions precisely because they handled a Schedule I substance.
Blanche's order invokes authority under the United Nations Single Convention on Narcotic Drugs, sidestepping the conventional rulemaking process to act immediately. Under the order's framework, the DEA must grant registration to qualifying applicants within six months of applying - unless doing so would be inconsistent with the public interest under 21 U.S.C. 823, the U.S. Code governing registration of manufacturers and distributors of controlled substances. The attorney general's order explicitly frames state licensing systems as the backbone of the new federal compliance architecture, a design that would theoretically preserve existing regulatory infrastructure rather than build a parallel one from scratch.
The potential upside for registered businesses is real. Law firm Foley Hoag has outlined likely benefits including potential access to export licenses, a pathway toward interstate commerce if and when federal or state law permits it, and improved standing for banking relationships, exchange listings, and mergers and acquisitions. For a sector that has spent years operating in a legal gray zone - unable to list on major U.S. exchanges, locked out of traditional credit markets, and taxed at rates that would cripple most industries - that's not nothing.
The Application's Liability Questions Are the Problem
Here's where it gets complicated. The seven-section registration form contains five liability questions, and at least two of them put applicants in a genuinely awkward position.
One asks whether anyone involved in the ownership or operation of the firm has previously manufactured, distributed, or dispensed a controlled substance without a DEA registration authorizing that activity. The answer, for virtually every state-licensed cannabis operator in existence, is yes - because until now, no such registration existed. The DEA application was never available. Applicants who answer affirmatively must supply names and a brief explanation. What weight the DEA will give that disclosure remains unclear; Cannabis Business Times sought comment from the DEA directly, and as of publication, no guidance had been issued.
A second question asks whether the firm will be handling or dispensing recreational marijuana. That's the sharper edge. Adult-use cannabis remains a Schedule I controlled substance at the federal level. Answering yes on a federal form is, in plain terms, an admission of federally prohibited activity - and the DEA reminds every applicant that intentionally furnishing false information carries penalties of up to four years in prison, a $250,000 fine, or both. Operators running dual-use facilities in states where both medical and adult-use cannabis are legal are thus asked to choose between candor and caution on a federal document that carries criminal penalties for dishonesty.
The form also accepts payment via automated clearing house bank transfer or PayPal - a $794 nonrefundable fee - which, under the circumstances, feels almost beside the point.
A Calculated Bet With Uneven Stakes
Jason Adelstone, an attorney with Harris Sliwoski, has described the registration decision as a "calculated bet." The legal fees alone - $10,000 to $15,000 for counsel to prepare an application, with additional costs depending on complexity and the number of registrations sought - are not trivial. The potential upside, he argues, could run into the hundreds of thousands or millions of dollars for operators who establish first-mover standing in what could become a federally recognized, and eventually global, medical cannabis market. The rescheduling order provides no guidance on future application windows or timelines, which means those who wait may find themselves negotiating from a weaker position later.
Trulieve, the Florida-based multistate operator with more than 200 medical-only dispensaries, didn't hesitate. The company filed its DEA registration applications on April 29, the same afternoon the portal opened. CEO Kim Rivers called it "a historic step forward." Trulieve's position - predominantly a medical operator, with roughly 85% of its nationwide store count in medical-only markets - makes the calculus relatively clean. For companies with significant adult-use exposure, it is decidedly less so.
What's striking here is the structural ambiguity the DEA has left in place. The dispensary portal is open. Whether separate portals will open for medical cannabis manufacturers - those cultivating, processing, packaging, and labeling products - and distributors remains unresolved. Those entities may be directed to use a standard DEA form, but no formal guidance has been issued. Operators are being asked to make consequential decisions against an incomplete regulatory picture, on a timeline set by a federal government that has spent the better part of five decades treating their businesses as criminal enterprises.
The Larger Timeline Adds Another Layer of Uncertainty
The expedited review window closes three days before the Department of Justice is scheduled to commence a broader administrative hearing process on June 29 - a process that will revisit the proposed rulemaking, originally advanced under President Biden, to reschedule all cannabis to Schedule III. That hearing is set to conclude no later than July 15, 2026. Which means operators who apply for expedited registration will submit their forms, pay their nonrefundable fees, and disclose potentially sensitive liability information - all before knowing whether adult-use cannabis will ultimately be rescheduled at all.
Decades of federal prohibition built a particular kind of institutional wariness inside the cannabis industry. Companies learned to operate without federal recognition, without conventional banking, without the protections available to legal businesses in virtually every other sector. The sudden availability of federal registration doesn't erase that history; it asks operators to trust a system that, until very recently, classified their entire enterprise as equivalent to heroin trafficking. For some, the first-mover argument wins out. For others, the liability exposure, the incomplete guidance, and the unresolved questions about dual-use businesses add up to a reason to wait - and watch how the early applicants fare.
